These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Messenger RNA vaccines against SARS-CoV-2. Topol EJ Cell; 2021 Mar; 184(6):1401. PubMed ID: 33740443 [TBL] [Abstract][Full Text] [Related]
5. Interrogation of the cellular immunome of cancer patients with regard to the COVID-19 pandemic. Donahue RN; Marté JL; Goswami M; Toney NJ; Tsai YT; Gulley JL; Schlom J J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33707314 [TBL] [Abstract][Full Text] [Related]
6. Repurposing CD8 Gujar S; Pol JG; Kim Y; Kroemer G Oncoimmunology; 2020 Jul; 9(1):1794424. PubMed ID: 32923158 [TBL] [Abstract][Full Text] [Related]
7. How 'killer' T cells could boost COVID immunity in face of new variants. Ledford H Nature; 2021 Feb; 590(7846):374-375. PubMed ID: 33580217 [No Abstract] [Full Text] [Related]
8. Viral Proteins under 70 Kilodaltons in Size Prevent the Development of Long-Lasting B-Cell Immune Memory and IgG2a Prevention in COVID-19 Vaccines. Martín Oncina J Crit Rev Immunol; 2020; 40(6):465-473. PubMed ID: 33900691 [TBL] [Abstract][Full Text] [Related]
9. Heterologous Immunity Between SARS-CoV-2 and Pathogenic Bacteria. Eggenhuizen PJ; Ng BH; Chang J; Cheong RMY; Yellapragada A; Wong WY; Ting YT; Monk JA; Gan PY; Holdsworth SR; Ooi JD Front Immunol; 2022; 13():821595. PubMed ID: 35154139 [TBL] [Abstract][Full Text] [Related]
10. 3CL hydrolase-based multiepitope peptide vaccine against SARS-CoV-2 using immunoinformatics. Jakhar R; Kaushik S; Gakhar SK J Med Virol; 2020 Oct; 92(10):2114-2123. PubMed ID: 32379348 [TBL] [Abstract][Full Text] [Related]
12. Immunity to glycan α-Gal and possibilities for the control of COVID-19. la Fuente J; Gortázar C; Cabezas-Cruz A Immunotherapy; 2021 Feb; 13(3):185-188. PubMed ID: 33307805 [No Abstract] [Full Text] [Related]
14. [Immune memory against SARS-CoV-2: Antibodies against the initial infection and memory B cells for the future ones]. Reynaud CA; Weill JC; Chappert P; Mahévas M Med Sci (Paris); 2021; 37(8-9):722-725. PubMed ID: 34346865 [No Abstract] [Full Text] [Related]
15. Adaptive immunity to SARS-CoV-2 and COVID-19. Sette A; Crotty S Cell; 2021 Feb; 184(4):861-880. PubMed ID: 33497610 [TBL] [Abstract][Full Text] [Related]
16. Ferritin nanoparticle-based SARS-CoV-2 RBD vaccine induces a persistent antibody response and long-term memory in mice. Wang W; Huang B; Zhu Y; Tan W; Zhu M Cell Mol Immunol; 2021 Mar; 18(3):749-751. PubMed ID: 33580169 [No Abstract] [Full Text] [Related]
17. Protective immunity against COVID-19: Unravelling the evidences for humoral vs. cellular components. Priyanka ; Choudhary OP; Singh I Travel Med Infect Dis; 2021; 39():101911. PubMed ID: 33186686 [No Abstract] [Full Text] [Related]
18. Can BCG vaccine protect against COVID-19 via trained immunity and tolerogenesis? Basak P; Sachdeva N; Dayal D Bioessays; 2021 Mar; 43(3):e2000200. PubMed ID: 33169410 [TBL] [Abstract][Full Text] [Related]
19. T Cells: Warriors of SARS-CoV-2 Infection. de Candia P; Prattichizzo F; Garavelli S; Matarese G Trends Immunol; 2021 Jan; 42(1):18-30. PubMed ID: 33277181 [TBL] [Abstract][Full Text] [Related]
20. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates. Ura T; Yamashita A; Mizuki N; Okuda K; Shimada M Vaccine; 2021 Jan; 39(2):197-201. PubMed ID: 33279318 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]